Latest Carpuject Stories

LAKE FOREST, Ill., Aug. 31 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's applications for six new presentations of therapeutic heparin in single- and multiple-dose vials. Heparin is used to prevent clot formation in central venous catheters and for anticoagulant (blood thinning) therapy, and is available in numerous delivery systems for...

LAKE FOREST, Ill., Aug. 11 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval and launch of oxaliplatin injection in the United States. The medication is a generic version of Sanofi-Aventis' Eloxatin(R), which posted 2008 U.S. sales of approximately $1.4 billion. Hospira's oxaliplatin injection is one of the first generic versions of this drug to come in solution form....

LAKE FOREST, Ill., June 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced agreements with MedAssets on intravenous (I.V.) solutions and gravity I.V. equipment, and a renewal of its agreement for infusion devices. The five-year MedAssets agreements are effective as of June 1, 2009, for I.V. solutions and equipment, and July 1, 2009, for infusion devices. These new agreements represent a first for Hospira...

LAKE FOREST, Ill., June 29 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for a 500 mg vial of azithromycin for injection in the ADD-Vantage(R) System. The anti-infective medication is a generic version of Pfizer's Zithromax(R) for injection. U.S. sales of generic and name-brand azithromycin for injection were approximately $40 million in 2008....

LAKE FOREST, Ill., June 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today announced that it will host a conference call to discuss its second-quarter 2009 results on Wednesday, July 29, 2009, at 8 a.m. Central time. The company will release its second-quarter 2009 results earlier that morning, before the U.S. stock market open and the conference call. A live webcast of the conference call will be...

-- Has Tentative FDA Approval and Expects Final Approval Shortly -- LAKE FOREST, Ill., June 18 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. District Court for the District of New Jersey has granted summary judgment of non-infringement in Hospira's favor with regard to Sanofi Aventis' chemotherapy medication Eloxatin(R), and that Hospira has tentative approval from the U.S. Food and Drug...

-- Prototype of the Innovative Combined Technology on Demonstration at AACN Expo -- LAKE FOREST, Ill., May 19 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today announced the coming integration of its clinician-friendly Symbiq(R) smart infusion pump and industry-leading EndoTool(R) glucose management software. A prototype of this technologically advanced combination system is being demonstrated at the...

- Shareholders Approve All Items - LAKE FOREST, Ill., May 14 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today held its 2009 Annual Meeting of Shareholders in Denver, Colo. The agenda included votes on three items and an update on the company's five-year progress and its strategy going forward. "We have made significant progress since becoming a public company in 2004, a testament to the strong foundation...

- Offers most complete product portfolio of important anti-infective - LAKE FOREST, Ill., May 7 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for a 10 gram vial of Sterile Vancomycin Hydrochloride, USP, an anti-infective medication. This approval means Hospira now offers the most complete product portfolio of this important drug, which is an...

LAKE FOREST, Ill., May 7 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced that the company will present at the Bank of America and Merrill Lynch 2009 Health Care Conference on Wednesday, May 13, 2009, in New York City. The presentation is scheduled to begin at 8:00 a.m. Eastern time on Wednesday, May 13, 2009. It will be available to all interested parties through a live audiocast accessible via the...